{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:21:16Z","timestamp":1793132476261,"version":"4.5.0"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.cytogfr.2023.12.007","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T12:06:00Z","timestamp":1704197160000},"page":"48-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Navigating IL-6: From molecular mechanisms to therapeutic breakthroughs"],"prefix":"10.1016","volume":"76","author":[{"given":"Akey Krishna","family":"Swaroop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeya","family":"Negi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esakkimuthukumar","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawahar","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnan","family":"Namboori P.K.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jubie","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2023.12.007_bib1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib2","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1002\/eji.200737772","article-title":"Historical insights into cytokines","volume":"37","author":"Dinarello","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/17512433.2022.2097905","article-title":"Current status and prospects of IL-6\u2013targeting therapy","volume":"15","author":"Narazaki","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/intimm\/dxu081","article-title":"Therapeutic uses of anti-interleukin-6 receptor antibody","volume":"27","author":"Kang","year":"2015","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0092-8674(89)90121-9","article-title":"Pleiotropy and redundancy: T cell-derived lymphokines in the immune response","volume":"57","author":"Paul","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-immunol-101220-023458","article-title":"IL-6 revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19","volume":"40","author":"Kishimoto","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib10","article-title":"Historical overview of the interleukin-6 family cytokine","volume":"217","author":"Kang","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib11","doi-asserted-by":"crossref","first-page":"a028415","DOI":"10.1101\/cshperspect.a028415","article-title":"Interleukin-6 family cytokines","volume":"10","author":"Rose-John","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-immunol-032713-120211","article-title":"Insights into cytokine\u2013receptor interactions from cytokine engineering","volume":"33","author":"Spangler","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib13","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.3390\/molecules27092696","article-title":"Novel small molecule inhibitors targeting the IL-6\/STAT3 pathway or IL-1\u03b2","volume":"27","author":"Yoo","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115327","article-title":"A panoramic review of IL-6: structure, pathophysiological roles and inhibitors","volume":"28","author":"Kaur","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib17","unstructured":"K.S. Akey, J. S, V. P, J. M, J. N, Dual modulation of IL-6 pathway by flavonoid- metal complexes as immune boosters for SARS-CoV-2 therapy, SPAST Abstracts. 1 (2021). https:\/\/spast.org\/techrep\/article\/view\/2989 (accessed July 25, 2023)."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cytogfr.2012.04.001","article-title":"Plasticity and cross-talk of Interleukin 6-type cytokines","volume":"23","author":"Garbers","year":"2012","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrrheum.2013.8","article-title":"The problem of choice: current biologic agents and future prospects in RA","volume":"9","author":"Choy","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib20","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.18632\/oncotarget.1410","article-title":"Targeting IL-11 signaling in colon cancer","volume":"4","author":"Ernst","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib21","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1084\/jem.169.1.333","article-title":"The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome","volume":"169","author":"Waage","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib23","first-page":"1","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","author":"Rose-John","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00384-018-3069-8","article-title":"Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases","volume":"33","author":"Nikolaus","year":"2018","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.891456","article-title":"Identification of IL-6 signalling components as predictors of severity and outcome in COVID-19","volume":"13","author":"Rodr\u00edguez-Hern\u00e1ndez","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib26","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.4049\/jimmunol.171.6.3202","article-title":"Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130","volume":"171","author":"Nowell","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib27","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1001\/jama.286.17.2107","article-title":"Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy","volume":"286","author":"Lindmark","year":"2001","journal-title":"Jama"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1359-6101(02)00027-8","article-title":"IL-6 in autoimmune disease and chronic inflammatory proliferative disease","volume":"13","author":"Ishihara","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cytogfr.2015.07.004","article-title":"Interleukin-6: biology, signaling and strategies of blockade","volume":"26","author":"Schaper","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155690","article-title":"Blocking only the bad side of IL-6 in inflammation and cancer","volume":"148","author":"Rose-John","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib31","article-title":"Leveraging decagonal in-silico strategies for uncovering IL-6 inhibitors with precision","author":"Akey","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","article-title":"INTERLEUKIN-6: from basic science to medicine\u201440 years in immunology","volume":"23","author":"Kishimoto","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib33","series-title":"Seminars in Immunology","first-page":"88","article-title":"A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy","author":"Tanaka","year":"2014"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/intimm\/dxq030","article-title":"IL-6: from its discovery to clinical applications","volume":"22","author":"Kishimoto","year":"2010","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-pharmtox-010611-134715","article-title":"Therapeutic targeting of the interleukin-6 receptor","volume":"52","author":"Tanaka","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejphar.2009.04.023","article-title":"IL-6-trans-signalling increases rapid-eye-movement sleep in rats","volume":"613","author":"May","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155577","article-title":"Therapeutic targeting of IL-6 trans-signaling","volume":"144","author":"Rose-John","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib38","doi-asserted-by":"crossref","first-page":"26059","DOI":"10.1074\/jbc.M115.649509","article-title":"Shedding of endogenous interleukin-6 receptor (IL-6R) is governed by a disintegrin and metalloproteinase (ADAM) proteases while a full-length IL-6R isoform localizes to circulating microvesicles","volume":"290","author":"Schumacher","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib39","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejcb.2010.10.007","article-title":"The soluble interleukin 6 receptor: generation and role in inflammation and cancer","volume":"90","author":"Chalaris","year":"2011","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib40","unstructured":"U. May, Role of IL-6 trans-signalling for sleep-wake behaviour of rats: generation of brain-specific sgp130-Fc transgenic mice; central blockade of IL-6 trans-signalling, PhD Thesis, 2010. https:\/\/macau.uni-kiel.de\/receive\/diss_mods_00005150?lang=de (accessed November 29, 2023)."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib41","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/14728222.2014.888417","article-title":"Targeting classical IL-6 signalling or IL-6 trans -signalling in depression?","volume":"18","author":"Maes","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib42","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2000080","article-title":"Proteolytic origin of the soluble human IL-6R in vivo and a decisive role of N-glycosylation","volume":"15","author":"Riethmueller","year":"2017","journal-title":"PLoS Biol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib44","doi-asserted-by":"crossref","first-page":"21612","DOI":"10.1038\/s41598-020-77884-4","article-title":"Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro","volume":"10","author":"Flynn","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1096\/fj.99-1003rev","article-title":"The soluble interleukin 6 receptor: mechanisms of production and implications in disease","volume":"15","author":"Jones","year":"2001","journal-title":"FASEB J."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib46","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib47","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2019.03.027","article-title":"Pleiotropy and specificity: insights from the interleukin 6 family of cytokines","volume":"50","author":"Murakami","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib48","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","article-title":"Targeting interleukin-6 signaling in clinic","volume":"50","author":"Kang","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.18311\/jnr\/2022\/28798","article-title":"Discovery of immunomodulators from plant kingdom targeting IL-6 for the effective management therapy of SARS-CoV-2","volume":"22","author":"Krishna Swaroop","year":"2022","journal-title":"J. Nat. Remedies"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib50","article-title":"Dual modulation of IL-6 pathway by flavonoid-metal complexes as immune boosters for SARS-CoV-2 therapy","volume":"1","author":"Akey","year":"2021","journal-title":"SPAST Abstr."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib51","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.4049\/jimmunol.0901528","article-title":"Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells","volume":"184","author":"Jones","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib52","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nsmb941","article-title":"Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor","volume":"12","author":"Skiniotis","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib53","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809976","article-title":"ADAM 17 selectively activates the IL \u20106 trans\u2010signaling\/ ERK MAPK axis in KRAS \u2010addicted lung cancer","volume":"11","author":"Saad","year":"2019","journal-title":"EMBO Mol. Med"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib54","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib55","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ni.2865","article-title":"Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin","volume":"15","author":"Mauer","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib56","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3892\/ijmm.2014.1825","article-title":"Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis","volume":"34","author":"Sommer","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib57","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","article-title":"Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer","volume":"19","author":"Lesina","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib58","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4049\/jimmunol.182.1.613","article-title":"Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis","volume":"182","author":"Nowell","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib59","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s12276-021-00649-0","article-title":"Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms","volume":"53","author":"Kang","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib60","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/43219","article-title":"Structure and function of a new STAT-induced STAT inhibitor","volume":"387","author":"Naka","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib61","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1385\/CRIAI:28:3:177","article-title":"IL-6: from laboratory to bedside","volume":"28","author":"Kishimoto","year":"2005","journal-title":"CRIAI"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib62","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib63","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/eji.1830181122","article-title":"Excessive production of interleukin 6\/B cell stimulatory factor-2 in rheumatoid arthritis","volume":"18","author":"Hirano","year":"1988","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib64","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/1744666X.2017.1295850","article-title":"The role and therapeutic targeting of IL-6 in rheumatoid arthritis","volume":"13","author":"Narazaki","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib65","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib66","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/annrheumdis-2012-202893","article-title":"Circulating plasmablasts\/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis","volume":"72","author":"Kerkman","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib68","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ccr.2007.12.020","article-title":"Autocrine IL-6 signaling: a key event in tumorigenesis?","volume":"13","author":"Grivennikov","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib70","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ccr.2009.01.009","article-title":"Inflammation and cancer: IL-6 and STAT3 complete the link","volume":"15","author":"Bromberg","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-8-159","article-title":"The role of IL-6 in the radiation response of prostate cancer","volume":"8","author":"Wu","year":"2013","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-12-26","article-title":"IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus","volume":"12","author":"Chen","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib73","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cam4.174","article-title":"Association between adjuvant regional radiotherapy and cognitive function in breast cancer patients treated with conservation therapy","volume":"3","author":"Shibayama","year":"2014","journal-title":"Cancer Med."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib74","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","article-title":"Interleukin-6 signaling pathway in targeted therapy for cancer","volume":"38","author":"Guo","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib75","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1126\/science.1140485","article-title":"Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production","volume":"317","author":"Naugler","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib77","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/CS20110340","article-title":"IL-6\/IL-6 receptor system and its role in physiological and pathological conditions","volume":"122","author":"Mihara","year":"2012","journal-title":"Clin. Sci."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib78","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1093\/carcin\/22.12.1947","article-title":"IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1","volume":"22","author":"Lin","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib79","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1038\/sj.onc.1206423","article-title":"A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells","volume":"22","author":"Jourdan","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib80","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib81","series-title":"Seminars in Cancer Biology","first-page":"359","article-title":"Hypermethylation of tumor suppressor genes in cancer","author":"Herman","year":"1999"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib82","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1158\/0008-5472.CAN-04-3589","article-title":"Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation","volume":"65","author":"Hodge","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib83","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1038\/sj.onc.1209615","article-title":"RB and cell cycle progression","volume":"25","author":"Giacinti","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib84","first-page":"824","article-title":"Design and synthesis of novel quercetin metal complexes as IL-6 inhibitors for anti-inflammatory effect in SARS-CoV-2","volume":"59","author":"Krishna Swaroop","year":"2022","journal-title":"Indian J. Biochem. Biophys. (IJBB)"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib85","doi-asserted-by":"crossref","first-page":"15959","DOI":"10.1073\/pnas.232432399","article-title":"Structure of the extracellular domains of the human interleukin-6 receptor \u03b1-chain","volume":"99","author":"Varghese","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib86","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1073\/pnas.84.24.9035","article-title":"Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors","volume":"84","author":"Ikebuchi","year":"1987","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib87","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cytogfr.2012.04.001","article-title":"Plasticity and cross-talk of interleukin 6-type cytokines","volume":"23","author":"Garbers","year":"2012","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib88","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1432-1033.1993.tb18138.x","article-title":"Recombinant soluble human interleukin-6 receptor: expression in Escherichia coli, renaturation and purification","volume":"216","author":"STOYAN","year":"1993","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib89","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/eji.1830180619","article-title":"Interleukin 6 is involved in interleukin 1-induced activities","volume":"18","author":"Helle","year":"1988","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib90","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.4049\/jimmunol.143.4.1206","article-title":"IFN-beta 2\/IL-6 augments the activity of human natural killer cells","volume":"143","author":"Luger","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115327","article-title":"A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors","volume":"28","author":"Kaur","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib92","article-title":"Role of pro-inflammatory cytokines released from microglia in Alzheimer\u2019s disease","volume":"3","author":"Wang","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib93","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.nbd.2008.12.007","article-title":"Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer\u2019s brain is mediated by the JNK-AP1 signaling pathway","volume":"34","author":"Vukic","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib94","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.4049\/jimmunol.181.10.7254","article-title":"Fibrillar amyloid-\u03b2 peptides activate microglia via TLR2: implications for Alzheimer\u2019s disease","volume":"181","author":"Jana","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib95","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.brainresrev.2011.01.002","article-title":"Interleukin-6, a mental cytokine","volume":"67","author":"Spooren","year":"2011","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib96","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbi.2010.10.015","article-title":"Immune modulation of learning, memory, neural plasticity and neurogenesis","volume":"25","author":"Yirmiya","year":"2011","journal-title":"Brain, Behav., Immun."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005518","article-title":"IL-6 mediated degeneration of forebrain GABAergic interneurons and cognitive impairment in aged mice through activation of neuronal NADPH oxidase","volume":"4","author":"Dugan","year":"2009","journal-title":"PloS One"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib98","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJM199109263251306","article-title":"Inflammatory bowle disease l., N","volume":"325","author":"Podolsky","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib100","first-page":"47","article-title":"Increased interleukin-6 levels, interleukin-6 receptor and gp130 expression in peripheral lymphocytes of patients with inflammatory bowel disease","volume":"228","author":"Holub","year":"1998","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib101","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0092-8674(89)90438-8","article-title":"Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130","volume":"58","author":"Taga","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib102","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/gut.36.1.45","article-title":"Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6","volume":"36","author":"Mitsuyama","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib103","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1385\/CRIAI:28:3:187","article-title":"Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer","volume":"28","author":"Atreya","year":"2005","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib104","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib105","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib106","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1600-0560.2010.01612.x","article-title":"The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis","volume":"37","author":"Kardaun","year":"2010","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib107","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4049\/jimmunol.181.1.669","article-title":"IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis","volume":"181","author":"Skov","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib108","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/jid.2013.170","article-title":"The IL23R A\/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients","volume":"133","author":"Di Meglio","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib109","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-\u03b1, IFN-\u03b3, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","volume":"2005","author":"Arican","year":"2005","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib110","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/jdv.12240","article-title":"Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway","volume":"28","author":"Balato","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib111","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib112","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/964069","article-title":"IL-6 as a druggable target in psoriasis: focus on pustular variants","volume":"2014","author":"Saggini","year":"2014","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib113","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/jid.2013.404","article-title":"IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions","volume":"134","author":"Croxford","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib114","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib115","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-eular.2360","article-title":"AB0037 Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human il-6 receptor (il-6r) alpha","volume":"72","author":"Rafique","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib116","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","article-title":"Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib117","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/annrheumdis-2011-200704","article-title":"A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate","volume":"71","author":"Mease","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib118","series-title":"MAbs","first-page":"773","article-title":"Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling","author":"Shaw","year":"2014"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib119","first-page":"1237","article-title":"ALX-0061, an Anti-IL-6R Nanobody\u00ae forUse in Rheumatoid Arthritis, demonstrates a different in vitro profile as compared to tocilizumab","volume":"8","author":"Van Roy","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib120","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/PPA.S41433","article-title":"Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review","volume":"7","author":"Al-Shakarchi","year":"2013","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib121","first-page":"75","article-title":"Review of tocilizumab in the treatment of rheumatoid arthritis","volume":"2","author":"Okuda","year":"2008","journal-title":"Biol.: Targets Ther."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib122","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000507451","article-title":"Combination of LMT-28 and metformin improves beneficial anti-inflammatory effect in collagen-induced arthritis","volume":"106","author":"Park","year":"2021","journal-title":"Pharmacology"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib123","doi-asserted-by":"crossref","first-page":"670","DOI":"10.5713\/ajas.19.0463","article-title":"In vitro and in vivo pharmacokinetic characterization of LMT-28 as a novel small molecular interleukin-6 inhibitor","volume":"33","author":"Ahn","year":"2020","journal-title":"Asian-Austral J. Anim. Sci."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib124","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9330439","article-title":"A GP130-targeting small molecule, LMT-28, reduces LPS-induced bone resorption around implants in diabetic models by inhibiting IL-6\/GP130\/JAK2\/STAT3 signaling","volume":"2023","author":"Liu","year":"2023","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib125","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s10753-021-01474-3","article-title":"PD-L1 regulates inflammation in LPS-induced lung epithelial cells and vascular endothelial cells by interacting with the HIF-1\u03b1 signaling pathway","volume":"44","author":"Zhao","year":"2021","journal-title":"Inflammation"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib126","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1016\/j.bmcl.2010.09.117","article-title":"A novel small-molecule inhibitor of IL-6 signalling","volume":"20","author":"Zinzalla","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib127","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/1535-7163.MCT-12-1082","article-title":"Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer","volume":"12","author":"Xu","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib128","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/cancers15020456","article-title":"Targeting interleukin-6\/glycoprotein-130 signaling by raloxifene or SC144 enhances paclitaxel efficacy in pancreatic cancer","volume":"15","author":"Hering","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib129","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s11030-022-10558-7","article-title":"Identification of small molecules as potential inhibitors of interleukin 6: a multi-computational investigation","volume":"27","author":"Tran","year":"2023","journal-title":"Mol. Divers."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib130","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/0960-894X(95)00362-W","article-title":"Synthetic inhibitors of interleukin-6 I: 2,3,7,8-tetrahydro-4-aryl-1H-cyclopent [e] imidazo [1,2-a]- pyridin-5(6H)-one and related compounds","volume":"5","author":"Tagat","year":"1995","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib131","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/0960-894X(95)00363-X","article-title":"Synthetic inhibitors of interleukin-6 II: 3,5-diaryl pyridines and meta-terphenyls","volume":"5","author":"Tagat","year":"1995","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112375","article-title":"Discovery of bazedoxifene analogues targeting glycoprotein 130","volume":"199","author":"Song","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib133","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.21873\/anticanres.15003","article-title":"Synergistic effect of bazedoxifene and PARP inhibitor in the treatment of ovarian cancer regardless of BRCA mutation","volume":"41","author":"Zhang","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib134","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1002\/jmv.27951","article-title":"Antiviral efficacy of selective estrogen receptor modulators against SARS-CoV-2 infection in vitro and in vivo reveals bazedoxifene acetate as an entry inhibitor","volume":"94","author":"Miao","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib135","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2022.5340","article-title":"Combined inhibition of IL\u20116 and IL\u20118 pathways suppresses ovarian cancer cell viability and migration and tumor growth","volume":"60","author":"Zhang","year":"2022","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173822","article-title":"Bazedoxifene exhibits anti-inflammation and anti-atherosclerotic effects via inhibition of IL-6\/IL-6R\/STAT3 signaling","volume":"893","author":"Luo","year":"2021","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib137","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.21873\/invivo.12135","article-title":"Raloxifene and bazedoxifene could be promising candidates for preventing the COVID-19 related cytokine storm, ARDS and mortality","volume":"34","author":"Smetana","year":"2020","journal-title":"Vivo"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib138","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-28612-1","article-title":"A validated LC-MS\/MS method for clinical pharmacokinetics and presumptive phase II metabolic pathways following oral administration of Andrographis paniculata extract","volume":"13","author":"Songvut","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib139","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1002\/ptr.7141","article-title":"Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial","volume":"35","author":"Zhang","year":"2021","journal-title":"Phytother. Res."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib140","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/jocd.13161","article-title":"A new proprietary gel containing glabridin, andrographolide, and apolactoferrin improves the appearance of epidermal melasma in adult women: a 6-month pilot, uncontrolled open-label study","volume":"19","author":"Cantelli","year":"2020","journal-title":"J. Cosmet. Dermatol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib141","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10067-009-1180-5","article-title":"Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial","volume":"28","author":"Burgos","year":"2009","journal-title":"Clin. Rheuma"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib142","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-020-01745-w","article-title":"Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial","volume":"20","author":"Ciampi","year":"2020","journal-title":"BMC Neurol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib143","doi-asserted-by":"crossref","unstructured":"C. Li, J. Fuchs, J. Lin, O.S.U. COLUMBUS, Novel Small Molecules Disabling the IL-6\/IL-6R\/GP130 Heterohexamer Complex, 2013. https:\/\/apps.dtic.mil\/sti\/citations\/ADA606135 (accessed November 29, 2023).","DOI":"10.21236\/ADA606135"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib144","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/cei.13258","article-title":"Novel small molecule IL\u20106 inhibitor suppresses autoreactive Th17 development and promotes Treg development","volume":"196","author":"Aqel","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib145","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1021\/ol017058i","article-title":"Short total synthesis of (+)-madindolines A and B","volume":"4","author":"Hirose","year":"2002","journal-title":"Org. Lett."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib146","doi-asserted-by":"crossref","first-page":"14728","DOI":"10.1073\/pnas.232562799","article-title":"Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130","volume":"99","author":"Hayashi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib147","doi-asserted-by":"crossref","first-page":"10822","DOI":"10.1021\/bi050439+","article-title":"Binding of madindoline A to the extracellular domain of gp130","volume":"44","author":"Saleh","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib148","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760971","article-title":"IL-6\/STAT3 is a promising therapeutic target for hepatocellular carcinoma","volume":"11","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115993","article-title":"Comparative appraisal of in vitro biological profile and in vivo wound healing attributes of bergenin and Bergenia ciliata (Haw.) Sternb","volume":"304","author":"Faiz","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib150","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/biom13030403","article-title":"Chemistry and pharmacology of bergenin or its derivatives: a promising molecule","volume":"13","author":"Salimo","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib151","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1039\/C8TB00672E","article-title":"Bergenin loaded gum xanthan stabilized silver nanoparticles suppress synovial inflammation through modulation of the immune response and oxidative stress in adjuvant induced arthritic rats","volume":"6","author":"Rao","year":"2018","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186592","article-title":"Micheliolide suppresses LPS-induced neuroinflammatory responses","volume":"12","author":"Sun","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib153","first-page":"175","article-title":"Micheliolide inhibits gastric cancer growth in vitro and in vivo via blockade of the IL-6\/STAT3 pathway","volume":"74","author":"Tang","year":"2019","journal-title":"Pharmazie"},{"key":"10.1016\/j.cytogfr.2023.12.007_bib154","doi-asserted-by":"crossref","first-page":"991","DOI":"10.21037\/atm-20-4987","article-title":"Micheliolide alleviates ankylosing spondylitis (AS) by suppressing the activation of the NLRP3 inflammasome and maintaining the balance of Th1\/Th2 via regulating the NF-\u03baB signaling pathway","volume":"8","author":"Tian","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104506","article-title":"Micheliolide ameliorates diabetic kidney disease by inhibiting Mtdh-mediated renal inflammation in type 2 diabetic db\/db mice","volume":"150","author":"Liu","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib156","unstructured":"Kahlon D.K., Lansdell T.A., Fisk J.S., et al. Nuclear factor-\u03baB mediated inhibition of cytokine production by imidazoline scaffolds. J Med Chem. 2009;52(5):1302\u20131309. S. Kaur, et al. Bioorganic & Medicinal Chemistry 28 (2020) 115327 16 https:\/\/doi.org\/10.1021\/jm8013162. - Google Search, (n.d.). https:\/\/www.google.com\/search?q=Kahlon+DK%2C+Lansdell+TA%2C+Fisk+JS%2C+et+al.+Nuclear+factor-%CE%BAB+mediated+inhibition+of+cytokine+production+by+imidazoline+scaffolds.+J+Med+Chem.+2009%3B52(5)%3A1302%E2%80%931309.+S.+Kaur%2C+et+al.+Bioorganic+%26+Medicinal+Chemistry+28+(2020)+115327+16+https%3A%2F%2Fdoi.org%2F10.1021%2Fjm8013162.&rlz=1C1CHBF_enIN949IN949&oq=Kahlon+DK%2C+Lansdell+TA%2C+Fisk+JS%2C+et+al.+Nuclear+factor-%CE%BAB+mediated+inhibition+of+cytokine+production+by+imidazoline+scaffolds.+J+Med+Chem.+2009%3B52(5)%3A1302%E2%80%931309.+S.+Kaur%2C+et+al.+Bioorganic+%26+Medicinal+Chemistry+28+(2020)+115327+16+https%3A%2F%2Fdoi.org%2F10.1021%2Fjm8013162.&gs_lcrp=EgZjaHJvbWUyBggAEEUYOdIBCDEyMjBqMGo3qAIAsAIA&sourceid=chrome&ie=UTF-8 (accessed November 30, 2023)."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib157","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.bmcl.2010.02.001","article-title":"Synthesis and biological evaluation of nitrogen-containing benzophenone analogues as TNF-\u03b1 and IL-6 inhibitors with antioxidant activity","volume":"20","author":"Bandgar","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib158","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1007\/s00044-011-9856-1","article-title":"Synthesis, biological evaluation, and pharmacokinetic profiling of benzophenone derivatives as tumor necrosis factor-alpha and interleukin-6 inhibitors","volume":"21","author":"Bandgar","year":"2012","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib159","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1021\/jm200946h","article-title":"Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents","volume":"54","author":"Wu","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib160","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.bmcl.2011.02.016","article-title":"Synthesis and biological evaluation of 4-styrylcoumarin derivatives as inhibitors of TNF-\u03b1 and IL-6 with anti-tubercular activity","volume":"21","author":"Upadhyay","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib161","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.bmcl.2014.03.081","article-title":"Synthesis and in vitro evaluation of anti-inflammatory activity of ester and amine derivatives of indoline in RAW 264.7 and peritoneal macrophages","volume":"24","author":"Furman","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cytogfr.2023.12.007_bib162","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/np100686a","article-title":"Blockade of IL-6 secretion pathway by the sesquiterpenoid atractylenolide III","volume":"74","author":"Kang","year":"2011","journal-title":"J. Nat. Prod."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610123000941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610123000941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T08:58:39Z","timestamp":1729069119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610123000941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":161,"alternative-id":["S1359610123000941"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2023.12.007","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating IL-6: From molecular mechanisms to therapeutic breakthroughs","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2023.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}